Published in Nat Biotechnol on June 19, 2011
Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics (2012) 3.05
Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet (2012) 2.39
Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics (2014) 2.37
Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics (2012) 2.29
Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med (2012) 2.06
Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods (2013) 2.04
A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med (2013) 1.69
Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods (2013) 1.54
Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Natl Acad Sci U S A (2012) 1.52
Translational biomarkers of acetaminophen-induced acute liver injury. Arch Toxicol (2015) 1.49
Development of a highly automated and multiplexed targeted proteome pipeline and assay for 112 rat brain synaptic proteins. Proteomics (2015) 1.46
Protein significance analysis in selected reaction monitoring (SRM) measurements. Mol Cell Proteomics (2011) 1.45
Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol Cell Proteomics (2011) 1.44
Lipocalin 2 deactivates macrophages and worsens pneumococcal pneumonia outcomes. J Clin Invest (2013) 1.32
Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics. Proteomics (2012) 1.30
Proteomics meets the scientific method. Nat Methods (2013) 1.30
Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res (2013) 1.20
Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics (2012) 1.08
Quantitative proteomics targeting classes of motif-containing peptides using immunoaffinity-based mass spectrometry. Mol Cell Proteomics (2012) 1.07
Absolute quantification of transcription factors during cellular differentiation using multiplexed targeted proteomics. Nat Methods (2013) 1.06
Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res (2012) 1.06
Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med (2014) 1.05
N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications. Mol Cell Proteomics (2013) 1.05
Mass spectrometry for translational proteomics: progress and clinical implications. Genome Med (2012) 1.02
Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry. Mol Cell Proteomics (2014) 1.02
Antibody colocalization microarray: a scalable technology for multiplex protein analysis in complex samples. Mol Cell Proteomics (2011) 1.02
Sequential multiplexed analyte quantification using peptide immunoaffinity enrichment coupled to mass spectrometry. Mol Cell Proteomics (2011) 1.01
Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MS. PLoS One (2014) 1.00
Screening for colorectal cancer: established and emerging modalities. Nat Rev Gastroenterol Hepatol (2011) 0.99
Mass spectrometric protein maps for biomarker discovery and clinical research. Expert Rev Mol Diagn (2013) 0.96
Affinity proteomics reveals elevated muscle proteins in plasma of children with cerebral malaria. PLoS Pathog (2014) 0.94
Precision of multiple reaction monitoring mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue. J Proteome Res (2012) 0.94
Targeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletion. J Proteome Res (2013) 0.93
A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci (2012) 0.92
Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation. PLoS Comput Biol (2013) 0.92
Identification of direct target engagement biomarkers for kinase-targeted therapeutics. PLoS One (2011) 0.92
Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification. Clin Lab Med (2011) 0.91
Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry Enables Multiplex, Quantitative Pharmacodynamic Studies of Phospho-Signaling. Mol Cell Proteomics (2015) 0.90
Review of software tools for design and analysis of large scale MRM proteomic datasets. Methods (2013) 0.90
Long-gradient separations coupled with selected reaction monitoring for highly sensitive, large scale targeted protein quantification in a single analysis. Anal Chem (2013) 0.90
Applications of targeted proteomics in systems biology and translational medicine. Proteomics (2015) 0.90
Multiplexed quantification of estrogen receptor and HER2/Neu in tissue and cell lysates by peptide immunoaffinity enrichment mass spectrometry. Proteomics (2012) 0.90
Discovery of colorectal cancer biomarker candidates by membrane proteomic analysis and subsequent verification using selected reaction monitoring (SRM) and tissue microarray (TMA) analysis. Mol Cell Proteomics (2014) 0.88
Enhancing bottom-up and top-down proteomic measurements with ion mobility separations. Proteomics (2015) 0.87
Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring. Clin Proteomics (2013) 0.87
Integrative analysis to select cancer candidate biomarkers to targeted validation. Oncotarget (2015) 0.86
Prediction of drug response and safety in clinical practice. J Med Toxicol (2012) 0.86
Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma. Mol Cell Proteomics (2015) 0.85
Proteomics in cancer biomarkers discovery: challenges and applications. Dis Markers (2015) 0.85
Anti-peptide monoclonal antibodies generated for immuno-multiple reaction monitoring-mass spectrometry assays have a high probability of supporting Western blot and ELISA. Mol Cell Proteomics (2014) 0.85
Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma. J Proteome Res (2013) 0.84
Bulked sample analysis in genetics, genomics and crop improvement. Plant Biotechnol J (2016) 0.84
An integrated quantification method to increase the precision, robustness, and resolution of protein measurement in human plasma samples. Clin Proteomics (2015) 0.84
Monitoring host responses to the gut microbiota. ISME J (2015) 0.84
Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Mol Cell Proteomics (2015) 0.84
The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science. J Transl Med (2014) 0.84
Proteomics of microparticles with SILAC Quantification (PROMIS-Quan): a novel proteomic method for plasma biomarker quantification. Mol Cell Proteomics (2015) 0.84
Antibody-Coupled Magnetic Beads Can Be Reused in Immuno-MRM Assays To Reduce Cost and Extend Antibody Supply. J Proteome Res (2015) 0.83
Targeted proteomics: a bridge between discovery and validation. Expert Rev Proteomics (2014) 0.83
Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling. Proc Natl Acad Sci U S A (2014) 0.83
Clinical proteomics and OMICS clues useful in translational medicine research. Proteome Sci (2012) 0.83
Mass spectrometry-based N-glycoproteomics for cancer biomarker discovery. Clin Proteomics (2014) 0.83
Multiple Reaction Monitoring Enables Precise Quantification of 97 Proteins in Dried Blood Spots. Mol Cell Proteomics (2015) 0.82
Expediting SRM assay development for large-scale targeted proteomics experiments. J Proteome Res (2014) 0.82
Using an isolated rat kidney model to identify kidney origin proteins in urine. PLoS One (2013) 0.82
Immobilized Metal Affinity Chromatography Coupled to Multiple Reaction Monitoring Enables Reproducible Quantification of Phospho-signaling. Mol Cell Proteomics (2015) 0.82
Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics (2012) 0.82
Current application of proteomics in biomarker discovery for inflammatory bowel disease. World J Gastrointest Pathophysiol (2016) 0.81
Analytical validation considerations of multiplex mass-spectrometry-based proteomic platforms for measuring protein biomarkers. J Proteome Res (2014) 0.81
Toward rapid, high-sensitivity, volume-constrained biomarker quantification and validation using backscattering interferometry. Anal Chem (2014) 0.81
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. Gastric Cancer (2015) 0.80
High-throughput fractionation of human plasma for fast enrichment of low- and high-abundance proteins. Blood Transfus (2012) 0.80
Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. Int J Mol Sci (2014) 0.80
Targeted multiplexed selected reaction monitoring analysis evaluates protein expression changes of molecular risk factors for major psychiatric disorders. Int J Neuropsychopharmacol (2014) 0.79
Protein target quantification decision tree. Int J Proteomics (2013) 0.79
Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM). Mol Cell Proteomics (2015) 0.79
Streamlining biomarker discovery. Nat Biotechnol (2011) 0.79
Sample displacement chromatography as a method for purification of proteins and peptides from complex mixtures. J Chromatogr A (2012) 0.79
Advances in Proteomic Technologies and Its Contribution to the Field of Cancer. Adv Med (2014) 0.79
Automated sample preparation platform for mass spectrometry-based plasma proteomics and biomarker discovery. Biology (Basel) (2014) 0.79
Systems Proteomics View of the Endogenous Human Claudin Protein Family. J Proteome Res (2016) 0.79
The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification. Expert Rev Proteomics (2015) 0.77
Determination of variation parameters as a crucial step in designing TMT-based clinical proteomics experiments. PLoS One (2015) 0.77
Serial analysis of 38 proteins during the progression of human breast tumor in mice using an antibody colocalization microarray. Mol Cell Proteomics (2015) 0.77
On protein abundance distributions in complex mixtures. Proteome Sci (2013) 0.77
Cancer biomarker discovery using DNA aptamers. Analyst (2016) 0.77
Indirect protein quantification of drug-transforming enzymes using peptide group-specific immunoaffinity enrichment and mass spectrometry. Sci Rep (2015) 0.77
Optimized Protocol for Quantitative Multiple Reaction Monitoring-Based Proteomic Analysis of Formalin-Fixed, Paraffin-Embedded Tissues. J Proteome Res (2016) 0.76
Both targeted mass spectrometry and flow sorting analysis methods detected the decreased serum apolipoprotein E level in Alzheimer's disease patients. Mol Cell Proteomics (2013) 0.76
A targeted proteomic strategy for the measurement of oral cancer candidate biomarkers in human saliva. Proteomics (2015) 0.76
PeptideManager: a peptide selection tool for targeted proteomic studies involving mixed samples from different species. Front Genet (2014) 0.76
Comprehensive maternal serum proteomics identifies the cytoskeletal proteins as non-invasive biomarkers in prenatal diagnosis of congenital heart defects. Sci Rep (2016) 0.76
Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Front Neurol (2015) 0.76
Accounting for population variation in targeted proteomics. J Proteome Res (2013) 0.75
Development of a Targeted Urine Proteome Assay for kidney diseases. Proteomics Clin Appl (2015) 0.75
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. Mol Cell Proteomics (2015) 0.75
Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples. Oncotarget (2016) 0.75
Preclinical evaluation of a TEX101 protein ELISA test for the differential diagnosis of male infertility. BMC Med (2017) 0.75
An extra dimension in protein tagging by quantifying universal proteotypic peptides using targeted proteomics. Sci Rep (2016) 0.75
Quantitative proteomics: challenges and opportunities in basic and applied research. Nat Protoc (2017) 0.75
Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A (2003) 10.82
Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol (2006) 10.14
Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics (2005) 8.92
Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2007) 6.96
Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol (2008) 6.38
Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res (2004) 5.57
High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteomics (2007) 4.72
Antibody validation. Biotechniques (2010) 4.42
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 4.36
High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat Methods (2009) 4.17
Isotope dilution--mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin Chem (1996) 3.97
Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics (2004) 3.57
Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res (2007) 3.48
Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem (2008) 3.23
Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res (2004) 2.85
A human proteome detection and quantitation project. Mol Cell Proteomics (2009) 2.80
Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem (2009) 2.77
On the meaning of "sensitivity". Clin Chem (1997) 2.43
Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2009) 2.42
An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics (2009) 2.40
The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem (2009) 2.23
Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res (2009) 2.20
The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods (2009) 2.19
Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification. Mol Cell Proteomics (2008) 2.11
The expanding role of mass spectrometry in metabolite profiling and characterization. Chembiochem (2005) 2.04
Increased selectivity, analytical precision, and throughput in targeted proteomics. Mol Cell Proteomics (2010) 1.71
Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? Clin Chem (2008) 1.66
The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cell Proteomics (2005) 1.63
A reagent resource to identify proteins and peptides of interest for the cancer community: a workshop report. Mol Cell Proteomics (2006) 1.60
Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol Cell Proteomics (2011) 1.54
Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol Cell Proteomics (2011) 1.52
The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem (2009) 1.36
Targeted proteomics of low-level proteins in human plasma by LC/MSn: using human growth hormone as a model system. J Proteome Res (2003) 1.24
Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications. Dis Markers (2010) 1.15
Affinity reagent resources for human proteome detection: initiatives and perspectives. Proteomics (2007) 1.11
The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol Ther (2009) 1.09
Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer. Proteomics Clin Appl (2011) 0.89
Restructuring proteomics through verification. Biomark Med (2010) 0.87
On the meaning of "sensitivity": a rejoinder. Clin Chem (1998) 0.81
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Estimation of individual admixture: analytical and study design considerations. Genet Epidemiol (2005) 11.00
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol (2003) 8.12
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
An empirical framework for binary interactome mapping. Nat Methods (2008) 6.59
Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell (2002) 6.29
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Reconstructing genetic ancestry blocks in admixed individuals. Am J Hum Genet (2006) 5.92
The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell (2005) 5.81
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet (2011) 5.62
Partial Correlation Estimation by Joint Sparse Regression Models. J Am Stat Assoc (2009) 5.41
Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39
A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature (2004) 5.24
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
Histone H3.3 is enriched in covalent modifications associated with active chromatin. Proc Natl Acad Sci U S A (2004) 4.88
Myc influences global chromatin structure. EMBO J (2006) 4.71
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol (2007) 4.67
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza. CMAJ (2009) 4.44
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 4.36
Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res (2006) 4.32
Global regulation of erythroid gene expression by transcription factor GATA-1. Blood (2004) 4.22
Edgetic perturbation models of human inherited disorders. Mol Syst Biol (2009) 3.96
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
Spatial smoothing and hot spot detection for CGH data using the fused lasso. Biostatistics (2007) 3.80
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev (2003) 3.79
The SOL Genomics Network: a comparative resource for Solanaceae biology and beyond. Plant Physiol (2005) 3.65
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Refractive error and ethnicity in children. Arch Ophthalmol (2003) 3.50
Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res (2007) 3.48
Comparative analysis of a large dataset indicates that internal transcribed spacer (ITS) should be incorporated into the core barcode for seed plants. Proc Natl Acad Sci U S A (2011) 3.41
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
A suite of algorithms for the comprehensive analysis of complex protein mixtures using high-resolution LC-MS. Bioinformatics (2006) 3.32
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med (2009) 3.17
Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res (2007) 3.13
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08
The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res (2006) 3.07
A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J (2002) 3.05
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A (2004) 2.99
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest (2011) 2.90
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Hlx is induced by and genetically interacts with T-bet to promote heritable T(H)1 gene induction. Nat Immunol (2002) 2.87
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell (2011) 2.86
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
A human proteome detection and quantitation project. Mol Cell Proteomics (2009) 2.80
Parental myopia, near work, school achievement, and children's refractive error. Invest Ophthalmol Vis Sci (2002) 2.78
The standard protein mix database: a diverse data set to assist in the production of improved Peptide and protein identification software tools. J Proteome Res (2007) 2.77
mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell (2009) 2.74
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Observed increase in local cooling effect of deforestation at higher latitudes. Nature (2011) 2.69
Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab (2006) 2.57
Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol (2006) 2.56
Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol (2006) 2.56
Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem (2006) 2.55
Electron transfer ion/ion reactions in a three-dimensional quadrupole ion trap: reactions of doubly and triply protonated peptides with SO2*-. Anal Chem (2005) 2.54
Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens (2009) 2.52
GATA-1-mediated proliferation arrest during erythroid maturation. Mol Cell Biol (2003) 2.52
Empirically controlled mapping of the Caenorhabditis elegans protein-protein interactome network. Nat Methods (2009) 2.50
An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics (2009) 2.40
Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol Cell Proteomics (2009) 2.39
Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics (2014) 2.37
Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia (2005) 2.35
The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. Proteomics Clin Appl (2008) 2.35
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med (2008) 2.31
LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate (2003) 2.28
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev (2003) 2.27
A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet (2002) 2.21
The completion of the Mammalian Gene Collection (MGC). Genome Res (2009) 2.21
Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res (2009) 2.20
Gas-phase concentration, purification, and identification of whole proteins from complex mixtures. J Am Chem Soc (2002) 2.18